Star, 27, stuns in ‘ultra-short' mini dress
BOUF products are priced between $29.95 and $39.95. Picture: Supplied
Clinton had been testing the products for 5 months before BOUF was released for general sale in Priceline. Picture: Instagram/IndyClinton
The working mums got to glam up for the event with a blowdry using the BOUF products before the event. Picture: Supplied
Guests ate a Mexican-style feast and sipped on cocktails. Picture: Supplied
'The nicest part of my transformation is how I feel. Even my nose job didn't give me the same confidence boost that my hair regrowth has. After struggling for so many years, I just feel like myself," Clinton told news.com.au.
Attendees were also gifted the products to take home. Picture: Instagram/EmDavies
The 'proprietary blend of botanicals' in the BOUF products took a team of hair microbiologists in Japan 7 years to perfect. Picture Supplied
Clearly, everyone had a whole lot of fun. Picture: Instagram/IndyClinton
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
20 minutes ago
- News.com.au
ASX health May winners: Sector rises 1.59pc but market volatility remains
The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump's trade and health policies continue to impact sector Lumos up 7.4% in May after several positive announcements including largest single purchase order for point-of-care respiratory test The S&P/ASX 200 Health Care Index rose 1.59% in May, easing from a 2.16% gain in April but still finishing in the green. However, the sector is still not faring well and is the worst-performing year-to-date, down 5.65%. The sector rose in line with broader markets in May with the S&P/ASX 200 gaining 4.20% as fears around escalating US tariffs and a potential US-China trade war eased, bringing relief to global markets. Morgans healthcare analyst Iain Wilkie told Stockhead that 2025 had been very volatile for the sector. "Each month seems to be either up or down and the sector hasn't gained any real momentum at this stage," he said. Wilkie said US President Donald Trump and his trade and health policies were still impacting the sector. "It's just uncertainty which is driving everything at the moment," he said. In May Trump signed an executive order lowering prices of US prescription medicines to bring them in line with other countries, a policy referred to as the 'most favored nation' (MFN). The MFN policy aims to link US drug prices to much lower prices overseas – what Trump referred to as 'equalizing' prices. Trump said the order aimed to cut US pharmaceutical prices from between 59% to 90% and sets price targets for drugmakers to meet within 30 days and warns that further action will be taken if they fail to make 'significant progress' toward those goals. In a release The White House said the US had less than 5% of the world's population and yet funds around three quarters of global pharmaceutical profits. "There's no clear path on what happens next and consequences pharmaceutical companies may face," Wilkie said. "But its just created further uncertainty in the healthcare and pharmaceutical sectors in an already uncertain time." How ASX biotechs performed in May CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP DVL Dorsavi Ltd $ 0.02 36.4% 10.97 IVX Invion Ltd $ 0.11 28.0% 8.47 CC5 Clever Culture $ 0.02 26.7% 33.55 VFX Visionflex Group Ltd $ 0.003 25.0% 8.42 NYR Nyrada Inc $ 0.18 24.1% 37.97 IIQ Inoviq Ltd $ 0.55 23.9% 63.07 OSX Osteopore Limited $ 0.02 21.4% 2.95 PEB Pacific Edge $ 0.09 18.7% 60.89 ICR Intelicare Holdings $ 0.01 14.3% 3.89 MVP Medical Developments $ 0.67 11.7% 75.48 PCK Painchek Ltd $ 0.06 11.5% 106.83 IRX Inhalerx Limited $ 0.03 11.1% 6.40 ALA Arovella Therapeutic $ 0.08 11.0% 88.79 IPD Impedimed Limited $ 0.03 10.0% 66.91 LGP Little Green Pharma $ 0.11 10.0% 34.96 ATH Alterity Therapeutics $ 0.01 10.0% 100.40 DOC Doctor Care Anywhere $ 0.11 10.0% 38.50 AGH Althea Group $ 0.03 8.7% 20.56 ALC Alcidion Group Ltd $ 0.09 8.6% 114.15 HMD Heramed Limited $ 0.01 8.3% 11.38 MDR Medadvisor Limited $ 0.09 8.1% 57.48 RAD Radiopharm $ 0.03 8.0% 65.35 LDX Lumos Diagnostics $ 0.03 7.4% 21.71 AVR Anteris Technologies $ 6.29 6.6% 99.41 AFP AFT Pharmaceuticals $ 2.60 6.1% 272.65 ARX Aroa Biosurgery $ 0.49 5.4% 165.55 UCM Uscom Limited $ 0.02 5.3% 4.76 RHC Ramsay Health Care $ 37.90 5.1% 7,049.83 CVB Curvebeam Ai Limited $ 0.09 4.9% 26.97 REG Regis Healthcare Ltd $ 8.13 4.9% 1,242.92 TRI Trivarx Ltd $ 0.01 4.8% 6.79 ACR Acrux Limited $ 0.02 4.3% 9.79 VLS Vita Life Sciences $ 1.89 4.1% 104.29 PGC Paragon Care Limited $ 0.40 3.9% 662.12 NSB Neuroscientific $ 0.06 3.8% 7.95 CMP Compumedics Limited $ 0.28 3.7% 53.82 SPL Starpharma Holdings $ 0.09 3.4% 38.48 NOX Noxopharm Limited $ 0.07 2.9% 21.04 GLH Global Health Ltd $ 0.08 2.6% 4.63 CMB Cambium Bio Limited $ 0.21 2.5% 3.75 PIQ Proteomics Int Lab $ 0.42 2.4% 59.56 SDI SDI Limited $ 0.85 2.4% 99.25 CSX Cleanspace Holdings $ 0.45 2.3% 34.81 ATX Amplia Therapeutics $ 0.05 2.0% 19.40 MVF Monash IVF Group Ltd $ 0.78 2.0% 301.97 IDX Integral Diagnostics $ 2.43 1.9% 870.95 EZZ EZZ Life Science $ 1.54 1.7% 72.65 IMC Immuron Limited $ 0.07 1.5% 15.67 FRE Firebrickpharma $ 0.07 1.5% 15.05 SHL Sonic Healthcare $ 26.62 1.4% 12,821.98 FPH Fisher & Paykel Healthcare $ 34.59 1.4% 6,585.46 IMR Imricor Med Systems $ 1.67 1.2% 541.55 OCC Orthocell Limited $ 1.27 1.2% 307.31 PME Pro Medicus Limited $ 280.98 0.9% 15,316.67 PAR Paradigm Biopharmaceuticals $ 0.31 0.8% 120.72 CTE Cryosite Limited $ 0.75 0.7% 36.61 CHM Chimeric Therapeutic $ 0.00 0.0% 8.06 IXC Invex Therapeutics $ 0.09 0.0% 6.99 COV Cleo Diagnostics $ 0.35 0.0% 27.74 IDT IDT Australia Ltd $ 0.10 0.0% 45.12 EYE Nova EYE Medical Ltd $ 0.13 0.0% 35.52 OCA Oceania Healthc Ltd $ 0.59 0.0% 427.30 EPN Epsilon Healthcare $ 0.02 0.0% 8.29 TD1 Tali Digital Limited $ 0.00 0.0% 3.30 OIL Optiscan Imaging $ 0.13 0.0% 112.77 PER Percheron $ 0.01 0.0% 10.87 OSL Oncosil Medical $ 1.20 0.0% 13.82 BIT Biotron Limited $ 0.00 0.0% 3.32 EOF Ecofibre Limited $ 0.02 0.0% 7.58 TRP Tissue Repair $ 0.19 0.0% 11.19 IBX Imagion Biosys Ltd $ 0.01 0.0% 2.42 SOM SomnoMed Limited $ 0.59 0.0% 129.66 ANR Anatara Ls Ltd $ 0.01 0.0% 1.07 HIQ Hitiq Limited $ 0.02 0.0% 7.57 ADR Adherium Ltd $ 0.01 0.0% 5.31 PSQ Pacific Smiles Grp $ 1.81 -0.3% 291.73 COH Cochlear Limited $ 271.60 -0.4% 17,779.29 CSL CSL Limited $ 247.16 -0.7% 119,986.49 TLX Telix Pharmaceutical $ 25.98 -0.8% 7,546.94 HLS Healius $ 0.88 -0.8% 635.37 ANN Ansell Limited $ 31.19 -0.9% 4,566.62 SNZ Summerset Grp Hldgs $ 10.21 -0.9% 2,461.11 MYX Mayne Pharma Ltd $ 4.80 -1.0% 376.51 RGT Argent Biopharma Ltd $ 0.09 -1.1% 6.86 PNV Polynovo Limited $ 1.27 -1.2% 870.46 PYC PYC Therapeutics $ 1.20 -1.2% 699.91 BDX Bcal Diagnostics $ 0.08 -1.3% 27.45 NEU Neuren Pharmaceuticals $ 13.85 -1.4% 1,765.00 RMD ResMed Inc. $ 37.58 -1.5% 22,360.10 IME Imexhs Limited $ 0.33 -1.5% 17.70 LTP LTR Pharma $ 0.32 -1.5% 34.71 AHC Austco Healthcare $ 0.31 -1.6% 112.86 RHY Rhythm Biosciences $ 0.06 -1.6% 17.87 ONE Oneview Healthcare $ 0.27 -1.9% 202.31 VHL Vitasora Health Ltd $ 0.04 -2.4% 66.24 MSB Mesoblast Limited $ 1.60 -2.4% 1,560.40 CYC Cyclopharm Limited $ 1.18 -2.5% 131.70 AHX Apiam Animal Health $ 0.39 -2.5% 71.74 EBO Ebos Group Ltd $ 34.69 -2.5% 1,365.85 IMM Immutep Ltd $ 0.28 -2.6% 407.57 VIT Vitura Health Ltd $ 0.07 -2.9% 45.03 CUV Clinuvel Pharmaceuticals $ 10.24 -3.0% 457.13 AVH Avita Medical $ 1.89 -3.1% 123.08 NAN Nanosonics Limited $ 4.39 -3.1% 1,282.02 NUZ Neurizon Therapeutic $ 0.15 -3.3% 68.92 MAP Microba Life Sciences $ 0.15 -3.3% 64.94 BMT Beamtree Holdings $ 0.28 -3.4% 81.15 SIG Sigma Health Ltd $ 3.06 -3.5% 17,428.00 MX1 Micro-X Limited $ 0.06 -3.5% 36.70 CGS Cogstate Ltd $ 1.30 -3.5% 219.41 NC6 Nanollose Limited $ 0.05 -3.8% 15.24 RCE Recce Pharmaceutical $ 0.34 -4.2% 90.39 AYA Artrya $ 0.73 -4.6% 82.43 ACW Actinogen Medical $ 0.02 -4.8% 63.54 DXB Dimerix Ltd $ 0.58 -4.9% 326.72 ACL Au Clinical Labs $ 2.78 -5.1% 395.94 EBR EBR Systems $ 1.09 -5.2% 465.57 NXS Next Science Limited $ 0.07 -5.6% 19.57 EMV Emvision Medical $ 1.68 -5.6% 140.67 AT1 Atomo Diagnostics $ 0.02 -5.9% 10.98 PTX Prescient Ltd $ 0.05 -6.0% 37.85 AGN Argenica $ 0.77 -6.1% 98.63 M7T Mach7 Tech Ltd $ 0.35 -6.7% 84.43 BOT Botanix Pharma Ltd $ 0.35 -6.8% 620.71 ZLD Zelira Therapeutics $ 0.46 -7.1% 5.71 SNT Syntara Limited $ 0.07 -7.1% 105.57 CAN Cann Group Ltd $ 0.01 -7.1% 8.09 TYP Tryptamine Ltd $ 0.03 -8.6% 44.45 NTI Neurotech International $ 0.02 -8.7% 22.04 SHG Singular Health $ 0.30 -9.1% 83.31 ECS ECS Botanics Holding $ 0.01 -9.1% 14.26 GSS Genetic Signatures $ 0.49 -9.3% 110.16 CBL Control Bionics $ 0.03 -9.7% 8.84 ILA Island Pharma $ 0.21 -10.6% 49.05 UBI Universal Biosensors $ 0.04 -10.6% 12.52 EMD Emyria Limited $ 0.03 -10.7% 13.75 TRU Truscreen $ 0.02 -11.1% 13.32 RHT Resonance Health $ 0.04 -11.6% 20.22 RAC Race Oncology Ltd $ 1.21 -12.0% 210.22 4DX 4DMedical Limited $ 0.31 -12.9% 146.64 CYP Cynata Therapeutics $ 0.17 -13.2% 37.28 CU6 Clarity Pharma $ 1.91 -13.8% 535.84 CDX Cardiex Limited $ 0.04 -16.1% 17.87 1AI Algorae Pharma $ 0.01 -16.7% 8.44 TRJ Trajan Group Holding $ 0.77 -16.8% 116.57 IMU Imugene Limited $ 0.01 -17.6% 112.01 MEM Memphasys Ltd $ 0.00 -18.2% 7.93 AVE Avecho Biotech Ltd $ 0.00 -20.0% 12.69 BP8 Bph Global Ltd $ 0.00 -20.0% 2.10 VBS Vectus Biosystems $ 0.05 -21.7% 2.50 CTQ Careteq Limited $ 0.01 -23.1% 2.37 1AD Adalta Limited $ 0.00 -33.3% 1.93 Inoviq (ASX:IIQ) rose ~24% in May and got hit with a speeding ticket by the ASX. The oncology play had no particular news out in May and attributed the increase to publication online of an abstract accepted by the American Society of Clinical Oncology (ASCO) for a poster presentation about results of its EXO-OC test for ovarian cancer. Inoviq said the result had already been released in December and referred to in subsequent business updates. "Some shareholders may have missed or misunderstood the significance of our 3 December 2024 ASX release and subsequent related updates noted above and may believe the Abstract contains new or better information, which is materially price sensitive, that is not the case in the company's view. The company said new information to be delivered in the poster presentation at the ASCO annual meeting on June 1 was "considered price sensitive". On June 2 Inoviq announced that new data presented at the ASCO meeting showed its EXO-OC test achieved 77% sensitivity at 99.6% specificity for detecting ovarian cancer at all stages. Clever Culture Systems (ASX:CC5) continued to build momentum in May and was up 26.7% for the month after announcing a positive quarterly update in April, including its second quarter of positive cashflow. Clever Culture is targeting profitability in FY25 and building a substantial sales pipeline to underpin growth in FY26 for its APAS Independence instruments, which remain the only US FDA-cleared AI technology for automated culture plate reading. Lumos Diagnostics (ASX:LDX) rose 7.4% in May after several positive announcements including the largest single purchase order to date for its FebriDx test, a rapid point-of-care (POC) diagnostic designed to differentiate between bacterial and non-bacterial acute respiratory infections. Developer and distributor of cost-saving solutions for hospitals, surgery centres, clinics and healthcare facilities across the US iMedical purchased US$126,000 worth of FebriDx tests. In May Lumos also expanded Medicare reimbursement coverage in the US for FebriDx. By the end of May Lumos had secured reimbursement from six out of seven US Medicare Administrative Contractors (MACs) representing over 85% of US Medicare payment coverage. And Australia's biggest private hospital operator Ramsay Health Care (ASX:RHC) rose 5.1% in May after providing a positive update on its 52.8% stake in European hospitals business Santé, with unaudited group revenue for the nine months period ending March 31, up by 5.1%.
News.com.au
24 minutes ago
- News.com.au
Byron Bay and Bondi ranked as some of the world's most ‘overhyped' destinations
They are the beaches along the east coast championed to the world as Australia's best. Byron Bay and Bondi have long been tourist postcard stops (particularly for backpackers) for decades on end, but a new report may well flip some of our most popular beaches on its head. A new survey has carved out the most overhyped beaches around the world — and the ones that actually live up to their insta-worthy promise. Ibiza Summer Villas, which is a service that specialises in 'curating unforgettable experiences through an exclusive portfolio of luxurious villa rentals across the stunning island of Ibiza' dished the dirt onthe most overhyped beaches in the world, versus the ones that genuinely live up to the hype. The survey ranked over 100 recognised beaches globally by 'combining publicly available traveller reviews, search interest on Google and TikTok, and annual rainfall data to assess weather reliability.' Each beach in focus was scored based on how often it disappointed versus how popular it was online. Topping the list in the first three positions were all Thailand-based — being Railay Beach (famous for its limestone cliffs and accessible only by boat), followed by Patong Beach (often billed as Thailand's party capital) and in third spot was Maya Bay (the stunning cove made famous by the film, The Beach). But coming in fourth place as the world's most 'overhyped' beach was Byron Bay in NSW — followed by the always popular, Bondi Beach. According to the survey, Byron Bay — despite the laid-back lifestyle and celebrity sightings — ranked poorly on satisfaction (with 1.57 per cent of reviews as negative versus the destination's high search volume) and had relatively high rainfall. Bondi Beach — known as one of the most recognisable beaches in the world — had many claim the reality of the location didn't quite live up to the expectation. The survey revealed that Bondi had the highest percentage of negative reviews relative to total reviews, with 2.70 per cent of visitors using words like 'disappointing' or 'overrated.' 'Overcrowding, commercialisation, and tourist fatigue are common themes [for Bondi] earning it a firm spot in fifth place on the overhyped list,' the survey said in a statement. The Bondi Beach reputation has received a rough serve this week — with research conducted by Cloudwards (a source of cloud and privacy software reviews, including popular categories such as cloud storage, VPN and password managers) named Bondi Beach as part of the top 20 most complained about beaches worldwide. The research claimed to 'meticulously' examine TripAdvisor reviews for 200 of the world's most popular beaches to determine 'which sandy shores are leaving visitors feeling salty'. It then ranked the beaches from 1 – being the most complained about, to 100, the least complained about. The study focused on four main areas of criticism – cleanliness, overcrowding, long queues and noise disruption. Coming in first was Waikiki Beach in Hawaii, followed by Venice Beach in LA and Playa Manueel Antonio in Costa Rica. Bondi Beach ranked ninth while Manly Beach secured the 20th spot. According to the study, Bondi has a complaint score of 57.1, a 'dirty' rating of 13 per cent, 'overcrowded' percentage of 75.9 and 'noise disruption' of 3.4 per cent.
News.com.au
an hour ago
- News.com.au
Wild moment burglar busts a move before allegedly robbing school
Wild footage has captured a man practising his dance moves before allegedly breaking into a school and stealing laptops and other tech equipment in Victoria's northwest. Police allege the man drove a silver Holden Commodore into the car park of a school in Sunbury on April 23. After exiting the car, CCTV footage captured the man lifting his hands up, spinning around, jumping and dancing while holding a torch in his hand. 'It is believed the man was Dancing In The Dark,' Victoria Police said in a statement. The man was feeling the beat and dancing around in circles for a more than 20 seconds before he began scoping out the property. CCTV footage also showed the man pointing his torch towards the security camera before he entered the building. After several minutes of walking around the school, the man allegedly broke into the building and stole three laptops and a projector valued at $5000. The man has been described as caucasian, aged in his 30s with a medium build and long, dark brown hair. He was wearing a red and black jumper with black runners, a red headband and blue gloves. Anyone who recognises the man or has information about the incident is urged to contact Crime Stoppers on 1800 333 000.
